Manja Meggendorfer
Overview
Explore the profile of Manja Meggendorfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
3432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Summerer I, Walter W, Meggendorfer M, Haferlach T, Dicker F, Hutter S, et al.
Blood Cancer J
. 2025 Mar;
15(1):29.
PMID: 40032819
No abstract available.
2.
Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Gotze K, Braitsch K, et al.
Leukemia
. 2025 Jan;
39(3):614-622.
PMID: 39779979
Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter...
3.
Morath O, Crodel C, Rinke J, Sander I, Tekbas A, Meggendorfer M, et al.
Hamostaseologie
. 2024 Dec;
PMID: 39708833
Background: The risk of thrombosis and bleeding in myelofibrosis (MF) has been historically underappreciated. We sought to investigate potential molecular and clinical risk factors for venous (VTE) and arterial (ATE)...
4.
Walter W, Iacobucci I, Meggendorfer M
Histopathology
. 2024 Oct;
86(1):134-145.
PMID: 39403021
B-acute lymphoblastic leukaemia (B-ALL) is a haematological disease resulting from haematopoietic system dysfunction, leading to the unchecked growth of immature B lymphoblasts. The disease's complexity is underscored by the spectrum...
5.
Walter W, Nadarajah N, Hutter S, Muller H, Haferlach C, Kern W, et al.
Leukemia
. 2024 Sep;
38(12):2644-2652.
PMID: 39341969
Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal disorders characterized by aberrant hematopoietic proliferation and an intrinsic risk of progression to blast phase. The WHO classification 2022 identifies chronic...
6.
Meggendorfer M, Haferlach T, Beykirch M, Petrides P
Haematologica
. 2024 Sep;
110(2):485-487.
PMID: 39323414
No abstract available.
7.
Montoro M, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, et al.
Blood
. 2024 Jul;
144(16):1722-1731.
PMID: 39074355
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53...
8.
Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, et al.
Leukemia
. 2024 Jul;
38(9):1992-2002.
PMID: 39033241
Mutations in the cohesin complex components (STAG2, RAD21, SMC1A, SMC3, and PDS5B) are recurrent genetic drivers in myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Whether the different cohesin subunit...
9.
Stengel A, Horst K, Kuhn C, Meggendorfer M, Kern W, Haferlach T, et al.
Blood Adv
. 2024 Jul;
8(15):4125-4128.
PMID: 38980314
No abstract available.
10.
Huber S, Wossidlo N, Haferlach T, Hutter S, Walter W, Pohlkamp C, et al.
Leukemia
. 2024 May;
38(7):1626-1629.
PMID: 38806631
No abstract available.